JP2005533053A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533053A5
JP2005533053A5 JP2004511321A JP2004511321A JP2005533053A5 JP 2005533053 A5 JP2005533053 A5 JP 2005533053A5 JP 2004511321 A JP2004511321 A JP 2004511321A JP 2004511321 A JP2004511321 A JP 2004511321A JP 2005533053 A5 JP2005533053 A5 JP 2005533053A5
Authority
JP
Japan
Prior art keywords
group
alkyl
amino
carbon atoms
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004511321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533053A (ja
JP4615998B2 (ja
Filing date
Publication date
Priority claimed from DE10226326A external-priority patent/DE10226326A1/de
Application filed filed Critical
Publication of JP2005533053A publication Critical patent/JP2005533053A/ja
Publication of JP2005533053A5 publication Critical patent/JP2005533053A5/ja
Application granted granted Critical
Publication of JP4615998B2 publication Critical patent/JP4615998B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004511321A 2002-06-11 2003-06-11 選択的活性エストロゲンとしての9−α置換のエストラトリエン Expired - Fee Related JP4615998B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
PCT/EP2003/006172 WO2003104253A2 (de) 2002-06-11 2003-06-11 9-alpha-substituierte estratriene als selektiv wirksame estrogene

Publications (3)

Publication Number Publication Date
JP2005533053A JP2005533053A (ja) 2005-11-04
JP2005533053A5 true JP2005533053A5 (https=) 2006-01-19
JP4615998B2 JP4615998B2 (ja) 2011-01-19

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004511321A Expired - Fee Related JP4615998B2 (ja) 2002-06-11 2003-06-11 選択的活性エストロゲンとしての9−α置換のエストラトリエン

Country Status (28)

Country Link
EP (1) EP1517914B1 (https=)
JP (1) JP4615998B2 (https=)
KR (1) KR101006612B1 (https=)
CN (1) CN1293090C (https=)
AR (1) AR040188A1 (https=)
AT (1) ATE303397T1 (https=)
AU (1) AU2003242683B9 (https=)
BR (1) BR0312140A (https=)
CA (1) CA2486495C (https=)
CR (1) CR10289A (https=)
CU (1) CU23414B7 (https=)
DE (2) DE10226326A1 (https=)
DK (1) DK1517914T3 (https=)
EA (1) EA008442B1 (https=)
EC (1) ECSP055530A (https=)
ES (1) ES2248770T3 (https=)
HR (1) HRP20050009B1 (https=)
IL (1) IL165321A (https=)
MX (1) MXPA04012491A (https=)
NO (1) NO329563B1 (https=)
PE (1) PE20040613A1 (https=)
PL (1) PL209910B1 (https=)
RS (1) RS50878B (https=)
TW (1) TWI286140B (https=)
UA (1) UA78062C2 (https=)
UY (1) UY27844A1 (https=)
WO (1) WO2003104253A2 (https=)
ZA (1) ZA200500217B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
ES2307064T3 (es) * 2003-11-26 2008-11-16 Bayer Schering Pharma Aktiengesellschaft Prevencion y tratamiento de enfermedades cardiacas hipertensivas por los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,5(10)-trien-3,16alfa-diol.
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EA018330B1 (ru) * 2008-02-13 2013-07-30 Байер Интеллекчуал Проперти Гмбх Система доставки лекарственного средства со стабилизирующим эффектом
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2010057594A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
EP3185881B1 (en) 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
JP2021535183A (ja) * 2018-09-07 2021-12-16 トラスティーズ・オヴ・ダートマス・カレッジ C19骨格およびステロイドならびにそれらの使用および製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
DE50014299D1 (de) * 1999-11-02 2007-06-14 Bayer Schering Pharma Ag 18-nor-steroide als selektiv wirksame estrogene
BR0109983A (pt) * 2000-04-12 2003-02-25 Schering Ag Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes

Similar Documents

Publication Publication Date Title
JP2005533053A5 (https=)
JP2004535412A5 (https=)
JP2013505929A5 (https=)
JP2007535595A5 (https=)
JP2005504811A5 (ja) 置換ペンタセン化合物、半導体デバイス及び物品
JP2010535870A5 (https=)
JP2008546770A5 (https=)
JP2010501478A5 (https=)
CA2796933A1 (en) 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
EP1849787A8 (en) Organosilicon compound
JP2012006843A5 (https=)
JP2006526587A5 (https=)
CA2586449A1 (en) Method for producing (4,5-dihydroisoxazol-3-yl)thiocarboxamidine salt c0mpound
JP2007517826A5 (https=)
JP2005526149A5 (https=)
JP2011524352A5 (https=)
JP2013518112A5 (https=)
JP2009522364A5 (https=)
JP2002544191A5 (https=)
JP2006509753A5 (https=)
JP2010516779A5 (https=)
JP2005528341A5 (https=)
JP2007210969A5 (https=)
JP2008280653A5 (https=)
JP2008533169A5 (https=)